Link Plus

LinkPlus Bio-Tech is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary "Linker-Plus" platform to design and optimize PROTAC (Proteolysis-Targeting Chimera) molecules that utilize the body's natural ubiquitin-proteasome system to eliminate disease-causing proteins. Its lead candidate, LT-002, is a potent and selective IRAK4 degrader currently being evaluated in Phase 1 clinical trials for the treatment of autoimmune and inflammatory conditions. LinkPlus aims to address high unmet medical needs by targeting proteins previously considered "undruggable" in the fields of oncology and immunology.